On January 5, 2021, upon the recommendation of its Nominating and Corporate Governance Committee the Board of Directors of Coherus BioSciences, Inc. increased the size of the Board from nine directors to ten directors and appointed Mr. Alan C. Mendelson and Mr. Mark D. Stolper to fill the vacancies created by such increase and the resignation of Christos Richards. Mr. Mendelson was appointed as a Class I director, with a term of office expiring at the Company’s 2021 annual meeting of stockholders until his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr. Stolper was appointed as a Class III director, with a term of office expiring at the Company’s 2023 annual meeting of stockholders and as a member of the Audit Committee until his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr. Mendelson, served as a partner at Latham & Watkins LLP from May 2000 to December 2020, where he held several leadership roles, including Co-Chair of the Emerging Companies Practice Group and Global Co-Chair of the Life Sciences Industry Group, and advised numerous private and public companies, primarily in the life sciences industry. Prior to joining Latham & Watkins LLP, Mr. Mendelson was a partner at Cooley LLP from February 1980 to May 2000. Mr. Stolper, has served as Executive Vice President and Chief Financial Officer of RadNet, Inc., Previously, Mr. Stolper served as a member of the board of directors of the following companies: 21st Century Oncology Holdings, Inc. from January 2018 to May 2020; Surgical Solutions LLC from 2015 to February 2017.